ASH 2020 | CAR T-cell therapy for relapsed ALL with CNS involvement
Sara Ghorashian, FRCPath, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK describes the findings of an international retrospective study of patients who were referred to CD19 CAR T-cell therapy for relapsed acute lymphoblastic leukemia (ALL) with CNS involvement. Previous clinical studies evaluating CAR T-cell therapies have excluded ALL patients with active CNS disease, so outcome data in these patients are currently lacking. Results from the toxicity profiles and outcomes in this study were favorable and it is hoped that this data will support the use of CD19 CAR-T in patients with CNS manifestations of ALL, particularly in countries in which these therapies are not currently approved for this indication. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
